The Netherlands: Scenic Biotech, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders, has closed a Series A financing of €28m (US$30.6m). Funds will be used to accelerate Scenic’s transition into a development stage company, advancing its in-house pipeline and supporting the creation of…
©2023 All rights reserved LaingBuisson 
